Israel-based Nucleai announced an ongoing translational research collaboration with Gilead Sciences supporting Gilead's global antibody-drug conjugate (ADC) clinical development programs, applying Nucleai's AI-powered Tissue Intelligence platform to generate spatial biomarkers and translational insights across multiple oncology indications.
Under the collaboration, Nucleai has analyzed large datasets of hematoxylin and eosin (H&E) and immunohistochemistry (IHC) whole-slide images drawn from several of Gilead's clinical studies. The platform integrates computational pathology, spatial biology, and clinical outcomes data to extract quantitative tissue features — mapping protein expression patterns, tumor heterogeneity, and microenvironmental context — and linking those features to patient response data. The company said the work has produced candidate spatial biomarkers intended for future scientific presentations and publications.
Financial terms were not disclosed.
The collaboration extends Nucleai's track record of pharma-facing platform engagements in the ADC space. The company has previously partnered with Bio-Techne Corporation (Nasdaq: TECH) on a spatial biology workflow that identified predictive biomarkers in melanoma patients from the SECOMBIT clinical trial, and joined CellCarta's Digital Pathology and AI Consortium alongside six other AI pathology firms in July 2026. For Gilead, the arrangement adds an AI tissue analytics layer to an ADC pipeline that has expanded aggressively through external transactions, including its acquisition of Germany-based Tubulis — which had originated from an exclusive option and license agreement signed in December 2024. A comparable AI-driven biomarker collaboration in the ADC space was struck by Tempus AI and Daiichi Sankyo in March 2026, in which Tempus deployed its PRISM2 multimodal foundation model to support patient stratification for an undisclosed ADC program.
Access the AllSci platform to explore the science behind the news.
Spot something wrong? Report an issue with this article